Twist Bioscience Corporation (TWST) Tops Q4 EPS by 16c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2020 Financial Results
November 23, 2020 7:01 AM EST-- Fiscal 2020 Revenues of $90.1M; Increase of 66% over $54.4M in Fiscal 2019 --
-- Strong Growth in Synthetic Biology, NGS Businesses --
-- Twist Biopharma Established 13 Partnerships, 8 with Milestones and/or Royalties in FY20 --
-- Expect Revenue of $110M to $118M for Fiscal 2021 --
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business... More
